Jiang Wu1, Yang Zhang1, Peng Yang1, Budbazar Enkhjargal1, Anatol Manaenko1, Jiping Tang1, William J Pearce1, Richard Hartman1, Andre Obenaus1, Gang Chen2, John H Zhang2. 1. From the Department of Neurosurgery (J.W., G.C.), the First Affiliated Hospital of Soochow University, Suzhou, China; and Department of Physiology (J.W., Y.Z., P.Y., B.E., A.M., J.T., W.J.P., R.H., A.O., J.H.Z.), School of Behavioral Science (R.H.), Department of Pediatrics (A.O.), and Department of Anesthesiology (J.H.Z.), Loma Linda University, CA. 2. From the Department of Neurosurgery (J.W., G.C.), the First Affiliated Hospital of Soochow University, Suzhou, China; and Department of Physiology (J.W., Y.Z., P.Y., B.E., A.M., J.T., W.J.P., R.H., A.O., J.H.Z.), School of Behavioral Science (R.H.), Department of Pediatrics (A.O.), and Department of Anesthesiology (J.H.Z.), Loma Linda University, CA. johnzhang3910@yahoo.com nju_neurosurgery@163.com.
Abstract
BACKGROUND AND PURPOSE: Recombinant osteopontin (rOPN) has been reported to be neuroprotective in stroke animal models. The purpose of this study is to investigate a potential role and mechanism of nasal administration of rOPN on preserving the vascular smooth muscle phenotype in early brain injury after subarachnoid hemorrhage (SAH). METHODS: One hundred and ninety-two male adult Sprague-Dawley rats were used. The SAH model was induced by endovascular perforation. Integrin-linked kinase small interfering RNA was intracerebroventricularly injected 48 hours before SAH. The integrin receptor antagonist fibronectin-derived peptide Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP), focal adhesion kinase inhibitor Fib-14, and Rac-1 inhibitor NSC23766 were administered 1 hour before SAH induction. rOPN was administered via the intracerebroventricular and nasal route after SAH. SAH grade, neurological scores, brain water content, brain swelling, hematoxylin and eosin staining, India ink angiography, Western blots, and immunofluorescence were used to study the mechanisms of rOPN on the vascular smooth muscle phenotypic transformation. RESULTS: The marker proteins of vascular smooth muscle phenotypic transformation α-smooth muscle actin decreased and embryonic smooth muscle myosin heavy chain (SMemb) increased significantly at 24 and 72 hours in the cerebral arteries after SAH. rOPN prevented the changes of α-smooth muscle actin and SMemb and significantly alleviated neurobehavioral dysfunction, increased the cross-sectional area and the lumen diameter of the cerebral arteries, reduced the brain water content and brain swelling, and improved the wall thickness of cerebral arteries. These effects of rOPN were abolished by GRGDSP, integrin-linked kinase small interfering RNA, and NSC23766. Intranasal application of rOPN at 3 hours after SAH also reduced neurological deficits. CONCLUSIONS: rOPN prevented the vascular smooth muscle phenotypic transformation and improved the neurological outcome, which was possibly mediated by the integrin receptor/integrin-linked kinase/Rac-1 pathway.
BACKGROUND AND PURPOSE: Recombinant osteopontin (rOPN) has been reported to be neuroprotective in stroke animal models. The purpose of this study is to investigate a potential role and mechanism of nasal administration of rOPN on preserving the vascular smooth muscle phenotype in early brain injury after subarachnoid hemorrhage (SAH). METHODS: One hundred and ninety-two male adult Sprague-Dawley rats were used. The SAH model was induced by endovascular perforation. Integrin-linked kinase small interfering RNA was intracerebroventricularly injected 48 hours before SAH. The integrin receptor antagonist fibronectin-derived peptide Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP), focal adhesion kinase inhibitor Fib-14, and Rac-1 inhibitor NSC23766 were administered 1 hour before SAH induction. rOPN was administered via the intracerebroventricular and nasal route after SAH. SAH grade, neurological scores, brain water content, brain swelling, hematoxylin and eosin staining, India ink angiography, Western blots, and immunofluorescence were used to study the mechanisms of rOPN on the vascular smooth muscle phenotypic transformation. RESULTS: The marker proteins of vascular smooth muscle phenotypic transformation α-smooth muscle actin decreased and embryonic smooth muscle myosin heavy chain (SMemb) increased significantly at 24 and 72 hours in the cerebral arteries after SAH. rOPN prevented the changes of α-smooth muscle actin and SMemb and significantly alleviated neurobehavioral dysfunction, increased the cross-sectional area and the lumen diameter of the cerebral arteries, reduced the brain water content and brain swelling, and improved the wall thickness of cerebral arteries. These effects of rOPN were abolished by GRGDSP, integrin-linked kinase small interfering RNA, and NSC23766. Intranasal application of rOPN at 3 hours after SAH also reduced neurological deficits. CONCLUSIONS: rOPN prevented the vascular smooth muscle phenotypic transformation and improved the neurological outcome, which was possibly mediated by the integrin receptor/integrin-linked kinase/Rac-1 pathway.
Authors: Ali Salahpour; Ivan O Medvedev; Jean-Martin Beaulieu; Raul R Gainetdinov; Marc G Caron Journal: Biol Psychiatry Date: 2006-05-19 Impact factor: 13.382
Authors: Dongxiao Shen; Jian Li; John J Lepore; Thomas J T Anderson; Sumita Sinha; Alexander Y Lin; Lan Cheng; Ethan David Cohen; Jesse D Roberts; Shoukat Dedhar; Michael S Parmacek; Robert E Gerszten Journal: Circ Res Date: 2011-07-21 Impact factor: 17.367
Authors: Andrew M Tan; Severine Stamboulian; Yu-Wen Chang; Peng Zhao; Avis B Hains; Stephen G Waxman; Bryan C Hains Journal: J Neurosci Date: 2008-12-03 Impact factor: 6.167
Authors: John H Zhang; Jerome Badaut; Jiping Tang; Andre Obenaus; Richard Hartman; William J Pearce Journal: Nat Rev Neurol Date: 2012-10-16 Impact factor: 42.937
Authors: Amandine Jullienne; Mary Hamer; Elizabeth Haddad; Alexander Morita; Peter Gifford; Richard Hartman; William J Pearce; Jiping Tang; John H Zhang; Andre Obenaus Journal: J Neurosci Res Date: 2019-03-20 Impact factor: 4.164